Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Novo Nordisk

This Little-Known Stock Just Doubled on Weight-Loss Drug News. Analysts Think It Has 400% Upside Potential From Here.

This weight-loss underdog doubled in a single day last week and could deliver even bigger rewards.

Barchart · Jan 28, 2025

Why isn’t Ozempic on Australia’s Pharmaceutical Benefits Scheme for weight loss? And should it be?

The drug is subsidised for treatment of type 2 diabetes but experts say it could help reduce other health problems associated with severe obesity

The Guardian - AU · Jan 27, 2025

Wegovy maker Novo Nordisk rebuked by watchdog over failure to disclose payments to UK health groups

Danish drug giant found to have failed to accurately report spending even after admitting to errors

The Guardian - UK · Jan 26, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

‘Skinny jabs’ are turning slimmers teetotal – and drinks companies are feeling the loss

As the public rejoice at shedding weight, the likes of Wegovy seem to be controlling other bad habits – in particular drinking to excess

The Guardian - UK · Jan 26, 2025

Novo Nordisk stock surges 7% on new weight-loss drug update

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Fortune · Jan 24, 2025

Novo Nordisk Stock Surges On Weight Loss Drug Data and Analysts Say It's Still a Buy

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight loss drug. Here's what you need to know.

Kiplinger · Jan 24, 2025

Ultrasound Weight Loss: GE HealthCare and Novo Nordisk’s Play

GLP-1 drugs have been all the rage for weight loss, but GE Healthcare and Novo Nordisk are working on a non-invasive approach to controlling metabolic functions

MarketBeat · Jan 22, 2025

Read news from The Economist, FT, and more,
with one subscription

LVMH dethrones Novo Nordisk as Europe's most valuable company

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Fortune · Jan 20, 2025

Novo Nordisk CEO attends crisis talks with Danish PM amid Trump's Greenland threats

Bosses from Fortune 500 Europe companies including Novo Nordisk, Lego, and Carlsberg met with the PM as Trump ups his threats over Greenland.

Fortune · Jan 17, 2025

How we diagnose and define obesity is set to change – here’s why, and what it means for treatment

Obesity is linked to many common diseases, such as type 2 diabetes, heart disease, fatty liver disease and knee osteoarthritis.

The Conversation · Jan 14, 2025

Trump Wants Greenland. Why That Could Be Bad News for Novo Nordisk Stock.

The pharma giant’s stock has been under pressure since the Greenland issue has been in the spotlight.

Barchart · Jan 13, 2025

Trump's Greenland Purchase Could Impact Drug Prices For Americans

President-elect Trump's interest in buying Greenland from Denmark could affect drug prices in the US.

Wegovy maker Novo Nordisk sponsored British pharmacies in pursuit of sales

Danish drug company gave money for Google ads to promote weight loss services and received data on web traffic and prescriptions

The Guardian - UK · Jan 4, 2025

Elon Musk Weighs In on Weight-Loss Drug Stocks. Is LLY or NVO a Better Buy?

Elon Musk’s preference for Eli Lilly’s Mounjaro over Novo Nordisk’s Ozempic has sparked increased interest in weight-loss drug stocks.

Barchart · Jan 2, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK · Dec 26, 2024

‘Wild west’: experts concerned by illegal promotion of weight-loss jabs in UK

Guardian review finds many online pharmacies flouting strict advertising rules that govern prescription-only drugs

FDA Approves Generic Version Of Diabetes Drug Liraglutide

FDA approves generic liraglutide for type 2 diabetes, offering affordability and addressing shortage.

Fortune · Dec 20, 2024

Novo Nordisk faces stock market bloodbath after drug trial disappoints

Shares in Novo Nordisk plunged 20% on Friday.

International Business Times · Dec 18, 2024

Ozempic May Face Investigation Over Vision-Threatening Condition In Some Patients

Danish health authorities asked the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat · Dec 18, 2024

Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

Fortune · Dec 4, 2024

Is Zepbound or Wegovy better for weight loss? New clinical trial reveals which medication sheds more pounds

Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables.

The Independent UK · Dec 4, 2024

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

In the first head-to-head test, people using Eli Lilly’s Zepbound lost just over 50 pounds while those using competitor Novo Nordisk’s Wegovy shed more than 33 pounds

The Conversation · Dec 1, 2024

Five things you should know about the HIV epidemic

It is 40 years since Aids was first identified. Major strides have been made since the spread of the virus reached epidemic proportions in 1995 when 3.3 million people were infected with HIV and just under one million people died.

Benzinga · Nov 29, 2024

What the Options Market Tells Us About Novo Nordisk

Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades.

Kiplinger · Nov 26, 2024

Stock Market Today: The S&P 500 Reclaims the 6K Level

Investors see Scott Bessent as a safe shepherd of the economy as the president-elect burnishes his "Tariff Man" reputation.

Benzinga · Nov 26, 2024

Biden Proposes Medicare, Medicaid Access For Popular Weight-Loss Drugs

The Biden Administration's proposal expands Medicare and Medicaid coverage for anti-obesity drugs, cutting costs for millions while addressing the obesity crisis.

1 … 18 19 20 21

Coverage From

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.